NCT00314210

Brief Summary

The primary objective of this study is to evaluate the efficacy of quetiapine SR compared to placebo in increasing time from randomisation to an anxiety event in patients with generalised anxiety disorder (GAD). PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.

Trial Health

98
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Strong global presence with extensive site network
Enrollment
575

participants targeted

Target at P75+ for phase_3

Timeline
Completed

Started Mar 2006

Geographic Reach
11 countries

114 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2006

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

April 11, 2006

Completed
2 days until next milestone

First Posted

Study publicly available on registry

April 13, 2006

Completed
1.3 years until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2007

Completed
Last Updated

March 25, 2009

Status Verified

March 1, 2009

First QC Date

April 11, 2006

Last Update Submit

March 24, 2009

Conditions

Keywords

Generalised Anxiety Disorder

Outcome Measures

Primary Outcomes (1)

  • Time from randomisation to occurrence of an anxiety event

Secondary Outcomes (5)

  • Occurrence of an anxiety event

  • Change from randomisation in HAM-A/CGI-S scores

  • In HAM-A psychic/somatic anxiety factor scores

  • In MADRS total score and in MADRS item 10 score (suicidal thought)

  • Change in Patient Reported Outcomes (PRO): QLESQ/PSQ/SDS

Interventions

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients will be male or female, 18 to 65 years of age (inclusive), with a diagnosis of GAD according to DSM-IV criteria 300.02 as assessed by the MINI.

You may not qualify if:

  • Patients suffering from depressive symptoms, defined as having a Montgomery-Åsberg Depression Rating Scale (MADRS) total score of 17 or more at the enrolment visit, will be excluded from participation in this study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (114)

Research Site

Mesa, Arizona, United States

Location

Research Site

Peoria, Arizona, United States

Location

Research Site

Phoenix, Arizona, United States

Location

Research Site

Fresno, California, United States

Location

Research Site

La Mesa, California, United States

Location

Research Site

Oceanside, California, United States

Location

Research Site

Redlands, California, United States

Location

Research Site

Coral Springs, Florida, United States

Location

Research Site

DeLand, Florida, United States

Location

Research Site

Fort Myers, Florida, United States

Location

Research Site

Gainsville, Florida, United States

Location

Research Site

Hialeah, Florida, United States

Location

Research Site

Jacksonville, Florida, United States

Location

Research Site

North Miami, Florida, United States

Location

Research Site

Orlando, Florida, United States

Location

Research Site

Saint Petersberg, Florida, United States

Location

Research Site

Atlanta, Georgia, United States

Location

Research Site

Columbus, Georgia, United States

Location

Research Site

Marietta, Georgia, United States

Location

Research Site

Roswell, Georgia, United States

Location

Research Site

Coeur d'Alene, Idaho, United States

Location

Research Site

Hoffman Estates, Illinois, United States

Location

Research Site

Libertyville, Illinois, United States

Location

Research Site

Indianapolis, Indiana, United States

Location

Research Site

Lafayette, Indiana, United States

Location

Research Site

Valparaiso, Indiana, United States

Location

Research Site

Prairie Village, Kansas, United States

Location

Research Site

Owensboro, Kentucky, United States

Location

Research Site

Paducah, Kentucky, United States

Location

Research Site

Shreveport, Louisiana, United States

Location

Research Site

Glen Burnie, Maryland, United States

Location

Research Site

Boston, Massachusetts, United States

Location

Research Site

Cambridge, Massachusetts, United States

Location

Research Site

Pittsfield, Massachusetts, United States

Location

Research Site

Saint Charles, Missouri, United States

Location

Research Site

Piscataway, New Jersey, United States

Location

Research Site

Cedarhurst, New York, United States

Location

Research Site

New York, New York, United States

Location

Research Site

Rochester, New York, United States

Location

Research Site

The Bronx, New York, United States

Location

Research Site

Avon Lake, Ohio, United States

Location

Research Site

Beechwood, Ohio, United States

Location

Research Site

Cincinnati, Ohio, United States

Location

Research SIte

Middleburg Heights, Ohio, United States

Location

Research Site

Toledo, Ohio, United States

Location

Research Site

Oklahoma City, Oklahoma, United States

Location

Research Site

Allentown, Pennsylvania, United States

Location

Research Site

Havertown, Pennsylvania, United States

Location

Research Site

Pittsburgh, Pennsylvania, United States

Location

Research Site

North Charleston, South Carolina, United States

Location

Research Site

Memphis, Tennessee, United States

Location

Research Site

DeSoto, Texas, United States

Location

Research Site

San Antonio, Texas, United States

Location

Research Site

Wichita Falls, Texas, United States

Location

Research Site

Midvale, Utah, United States

Location

Research Site

Richmond, Virginia, United States

Location

Research Site

Brisbane, Queensland, Australia

Location

Research Site

Everton Park, Queensland, Australia

Location

Research Site

West Burleigh, Queensland, Australia

Location

Research Site

Malvern, Victoria, Australia

Location

Research Site

Prahran, Victoria, Australia

Location

Research Site

Edmonton, Alberta, Canada

Location

Research Site

Bathurst, New Brunswick, Canada

Location

Research Site

Hamilton, Ontario, Canada

Location

Research Site

Kingston, Ontario, Canada

Location

Research Site

Orléans, Ontario, Canada

Location

Research Site

Toronto, Ontario, Canada

Location

Research Site

Waterloo, Ontario, Canada

Location

Research Site

Gatineau, Quebec, Canada

Location

Research Site

Montreal, Quebec, Canada

Location

Research Site

Helsinki, Finland

Location

Research Site

Joensuu, Finland

Location

Research Site

Kuopio, Finland

Location

Research Site

Oulu, Finland

Location

Research Site

Pori, Finland

Location

Research Site

Seinäjoki, Finland

Location

Research Site

Turku, Finland

Location

Research Site

Berlin, Germany

Location

Research Site

Göttingen, Germany

Location

Research Site

Jena, Germany

Location

Research Site

Leipzig, Germany

Location

Research Site

München, Germany

Location

Research Site

Naumburg, Germany

Location

Research Site

Nuremberg, Germany

Location

Research Site

Schwerin, Germany

Location

Research Site

Siegen, Germany

Location

Research Site

Balassagyarmat, Hungary

Location

Research Site

Budapest, Hungary

Location

Research Site

Győr, Hungary

Location

Research Site

Gyula, Hungary

Location

Research Site

Kecskemét, Hungary

Location

Research Site

Nyíregyháza, Hungary

Location

Research Site

Bandung, West Java, Indonesia

Location

Research Site

Jakarta, Indonesia

Location

Research Site

Cebu City, Philippines

Location

Research Site

Davao City, Philippines

Location

Research Site

Mandaluyong, Philippines

Location

Research Site

Manila, Philippines

Location

Research Site

Quezon City, Philippines

Location

Research Site

Moscow, Russia

Location

Research Site

Saint Petersburg, Russia

Location

Research Site

Saratov, Russia

Location

Research Site

Seoul, South Korea

Location

Research Site

Reading, Berkshire, United Kingdom

Location

Research Site

Crawley, West Sussex, United Kingdom

Location

Research Site

Blackpool, United Kingdom

Location

Research Site

Bolton, United Kingdom

Location

Research Site

Cardiff, United Kingdom

Location

Research Site

Chorley, United Kingdom

Location

Research Site

Coventry, United Kingdom

Location

Research Site

Glasgow, United Kingdom

Location

Research Site

Hamilton, United Kingdom

Location

Research Site

Liverpool, United Kingdom

Location

Research Site

Manchester, United Kingdom

Location

Related Publications (1)

  • Sheehan DV, Svedsater H, Locklear JC, Eriksson H. Effects of extended-release quetiapine fumarate on long-term functioning and sleep quality in patients with Generalized Anxiety Disorder (GAD): data from a randomized-withdrawal, placebo-controlled maintenance study. J Affect Disord. 2013 Dec;151(3):906-13. doi: 10.1016/j.jad.2013.07.037. Epub 2013 Aug 16.

MeSH Terms

Conditions

Anxiety DisordersGeneralized Anxiety Disorder

Condition Hierarchy (Ancestors)

Mental Disorders

Study Officials

  • Martin Brecher, MD

    AstraZeneca

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
DOUBLE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

April 11, 2006

First Posted

April 13, 2006

Study Start

March 1, 2006

Study Completion

August 1, 2007

Last Updated

March 25, 2009

Record last verified: 2009-03

Locations